Table 8.

Quality indicators for EET in dysplastic BE

Metric	Numerator	Denominator	Type	Threshold
For patients in whom a diagnosis of dysplasia has been made, the rate at which the reading is made by a GI pathologist or confirmed by a second pathologist before embarking on EET	Number of patients whose dysplasia diagnosis is made by a GI pathologist or a second pathologist before receiving EET	All patients who receive EET for treatment of dysplasia	Process	90 (75–100)
The rate at which CEN is achieved by 18 mo in patients with Barrett’s-related dysplasia or intramucosal cancer referred for EET	Patients who are referred for EET for treatment of Barrett’s-related dysplasia or intramucosal cancer who achieve CED within 18 mo	All patients who are referred for EET for treatment of Barrett’s-related dysplasia or intramucosal cancer	Outcome	80 (70–95)
The rate at which CEIM is achieved by 18 mo in patients with Barrett’s-related dysplasia and intramucosal cancer referred for EET	Patients who are referred for EET for treatment of Barrett’s-related dysplasia or intramucosal cancer who achieve CEIM within 18 mo	All patients who are referred for EET for treatment of Barrett’s-related dysplasia or intramucosal cancer	Outcome	70 (50–80)
The rate at which adverse events are being tracked and documented in individuals post-EET	Adverse events that are tracked and documented	All endoscopic procedures involving EET	Process	90 (50–100)

BE, Barrett’s esophagus; CED, complete eradication of dysplasia; CEIM, complete eradication of intestinal metaplasia; CEN, complete eradication of neoplasia; EET, endoscopic eradication therapy; GI, gastrointestinal.

Adapted from Wani et al. (225).